Predicting PSA50 response to [Formula: see text]Lu-PSMA therapy using machine learning and automated total tumor volume.

ABSTRACT: The ¹⁷⁷Lu-PSMA therapy is an established treatment for metastatic castration-resistant prostate cancer (mCRPC), targeting the prostate-specific membrane antigen (PSMA). Despite well-established correlations between ⁶⁸Ga-PSMA PET/CT imaging and outcome, predicting individual patient responses remains a significant challenge. This study introduces an automated method for computing the total tumor volume (TTV) from ⁶⁸Ga-PSMA PET/CT imaging and develops predictive models to assess patient biological response via the PSA50 criterion. A retrospective analysis was conducted on a real-world data cohort of 139 mCRPC patients treated in our institution. TTV was automatically extracted from PET/CT images and correlated with treatment response, defined by PSA50 criteri

SUBMITTER: Rios-Sanchez E 

PROVIDER: S-EPMC12605838 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature